Gynecologic oncologist at the University Hospital Mannheim and the Medical Faculty Mannheim of Heidelberg University, Germany. Head of the Section Conservative Gynecologic Oncology and the Gynecologic Clinical Trials Unit at the University Hospital Mannheim. Co-chair of the AGO Study Group and member of the Scientific Board of the GBC.

Prof. Frederik Marmé has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Daiichi Sankyo, EISAI, GenomicHealth, Gilead Sciences, GSK, Immunicom, INCYTE, MSD, Novartis, Pfizer, Lilly, Roche, Böhringer-Ingelheim, Myriad Genetics, Seagen/Pfizer, Novocure, Menarini Stemline, BIONTECH, Nerviano Medical Sciences, and Novartis.​

No financial interest: AGO Research GmbH, German Breast Group, Vaccibody